



Universidad Zaragoza

Biomagnetism-II

(Synthetic magnetic nanoparticles, their biomedical applications and toxicity)

Fernando Palacio Instituto de Ciencia de Materiales de Aragón. CSIC – Universidad de Zaragoza palacio@unizar.es

IEEE Summer School, 9-14 Jun. 2013



Outline P.2

In this 2nd part we will cover:

- Magnetic nanoparticles functionalities of biomedical interest:
 - moving
 - sensing
 - imaging
 - heating
- Multifunctionality
- A word on toxicological issues
- Hemocompatibility



The magnetic functionality









Magnetic force F_m



A force will be experienced provided there is a field gradient. More intuitively, we can relate F_m to the differential of the magnetostatic field energy density **B**·**H**/2:

$$F_m = V_m \Delta \chi \nabla (B \cdot H/2)$$

Thus if $\Delta \chi > 0$, F_m acts in the direction of the steepest ascent of the energy density scalar field.



DRIVING

Targeted drug delivery

i.e. retaining drugs in areas of low blood irrigation or easily accessible by magnetic forces.











O. Kreft, Angew. Chem. Int. Edn 2007 46 5605







B. Polyak et al. PNAS 105, 698 (2008)



Requirements for a good biosensor:

- Stable
- Highly specific
- Independent from external parameters (temperature, pH, others)
- Precise
- Reproducible
- Low electronic noise
- Biocompatible



Biofunctional membrane

- Enzimes ۲
- Proteins ۲
- Antibodies •
- Receptors ۲
- Microbes ۲
- Organelles ٠
- Animal cells •
- Plant cells •
- Animal tissues
- Plant tissues



Transducer



Implantable Biosensor

SENSING







Implantable Biosensor

SENSING





Nanobeads for a biosensor

SENSING









Doping control sensor

Antibody: AS143 (anti Methylboldenone androgenic anabolic steroid)





Doping control sensor



Antibody: AS143 (anti Methylboldenone androgenic















Low field 0.2 T MRI Imager by Esaote (for ariticulations)







R. Weissleder et el., Nature Med. 6(2000)351



MRI angiography by use of CA (contrast enhanced MRA)

- MRI able to evaluate the blood vessels noninvasively, known as MR angiography (MRA).
- MRA can evaluate blood vessels of the head and neck to detect vessel narrowing (stenosis), blood vessel blockage, cerebral aneurysm, arteriovenous malformation (AVM) and blood vessel dissection. This technique may be utilized for evaluation of both arteries and veins.

Contrast enhanced MRA utilizes an intravenous injection of MRI contrast media (Gd-DTPA). This safe technique does not require hospital admission or arterial injection, unlike conventional angiography.



IMAGING

17







MRI intensity (and therefore the contrast) depends on:

Intrinsic parameters:

- local proton density N(H), (water, fat, ...)
- relaxation times, T₁, T₂
- magnetic susceptibility differences

Extrinsic parameters:

- magnetic field
- timing of the pulse sequences (TE, TR)
- contrast agents (CA)





MRI signal is $s(t) = N(H) e^{-TE/T2^*} (1 - e^{-TR/T1})$

With CA it is possible to change the nuclear relaxation times (more efficient than protons' density differences) and so to obtain a better image contrast and pathology evidence





MRI signal is $s(t) = N(H) e^{-TE/T2^*} (1 - e^{-TR/T1})$

- Efficacy of a contrast agent in reducing T₁ or T₂ is evaluated by measuring the relaxivity r_i (i=1,2), that represents the relaxation rate of hydrogen nuclei in presence of 1mM of contrast agent
- The relaxation rate is the sum of the diamagnetic contribution (absence of CA) and the praramagnetic one (presence of CA)

$$\frac{1}{T_i} = \frac{1}{T_{i,d}} + \frac{1}{T_p} \qquad \qquad \frac{1}{T_i} = R_i = \frac{1}{T_{i,d}} + \frac{r_i c}{r_i c}$$

c = concentration of CA expressed in mM/L





- Huge magnetic moments as compared to Gd chelates
- Proton relaxation is affected by the large magnetic field heterogeneity in the vecinity of the particles
- Can induce >10 fold increase in proton relaxivities
- Shortening of relaxation times, particularly T₂ (*negative* contrast)
- Good spacial resolution, of the order of single cell detection (10 - 50 μm³)





0.2 0.5 1.5 T

r1 100 a) 10 r_I (mM_{Fe}⁻¹ s⁻¹ Α B - Endorem 0,1 0,1 10 100 0,01 ν (MHz)

A = 7.4 nm B = 8.6 nm C = 10.8 nm D = 15 nm

22





A = 7.4 nm B = 8.6 nm C = 10.8 nm D = 15 nm







$r_{1,2}$ dependence with size

MRI imagens



H. Amiri, et al., Magn. Res. in Medicine, 66, 1715-1721, (2011)



 H_c

Magnetic heating

HEATING

Magnetic systems can convert energy into heat under the effects of an alternating magnetic field

- inductive heating (eddy currents)
- hysteresis losses

h

$$P_{FM} = -\mu_0 f \oint H dM$$





No relevant at low ac magnetic fields





Superparamagnetic particles





Neél relaxation

Rotational Brownian motion

$$P_{SPM} = -\frac{1}{2}\mu_0\chi''\omega H_0^2$$



Biological limitations $50 \text{ kHz} \leq f \leq 1200 \text{ kHz},$ H < 15 kA/m $(H \cdot f) \text{max} = 485 \text{ kHz} \cdot \text{kA/m}$

After Brezovich [Med. Phys. Monograph 1988 16 82]

"test person had a sensation of warmth, but was able to withstand the treatment for more than one hour without major discomfort"

Standard values for comparative purposes: H = 4.85 kA/m, f = 100 kHz

 $P_{SPM} = -\frac{1}{2}\mu_0\chi''\omega H_0^2$



Direct injection of MNP into the tumor: clinical phase II



Clinical Results

Phase I/II (feasibility) Study: Nano-cancer therapy on Glioblastoma (brain tumor trial) [3/2003-12/2004].



- All study patients (14) showed <u>no side effects</u> of the Nano-cancer therapy (2 patients fell asleep during therapy and had to be woken up after the therapy time of 60 min)
- On all study patients therapeutical temperatures of up to and more than 50°C inside the tumor were achieved.
- Indication for a local effectiveness.
- 1 patient in complete remission since 2.5 years.
- · Rationale for a study of effectiveness.

Director of Study: Prof. Dr. med. Klaus Maier-Hauff, ZE Neurosurgery, Bundeswehrkrankenhaus Berlin

Selte 9 / Dr. Dr. Dietmar Wechsler





Direct injection of MNP into the tumor: clinical phase II





Direct injection is

- non-selective
- contaminates healthy tissues
- only valid for large tumors
- good heating efficiency as doses can be very high

Biological vectorisation is

- highly selective (specific therapeutic target)
- heating is very localised
- valid for micro-tumors (preventive)
- heating efficiency is linked to the number of MNP recognaising the target



HEATING







Biological applications: H \cdot f < 4.85 \cdot 10⁸ A/m \cdot s

H < 15 A/m, f < 400 kHz



HEATING

Specific Loss Power of particles of 10.8 and 15 nm as compared with commercial products.



Multifunctionality





Biomedical Applications of Magnetic Nanoparticles





Biomedical Applications of Magnetic Nanoparticles



From A. Ito et al., J Biosc. and Bioengin. 100(2005)1



Tailoring MNP with polymers



A. Millán and F. Palacio, Applied Organometallic Chemistry, 15, 396-400 (2001)

A. Millán, F. Palacio et al., Acta Materialia 55, 2201-9 (2007)

A. Millán, F. Palacio et al., Patent ES2308901B1



Tailoring MNP with polymers

An easy route for functionalisation: Michael reaction



R. Piñol, A. Millán, F. Palacio et al., Patent P201031493



Multifunctional MNP for Biomedical Applications





Tailoring MNP with polymers

Multifunctional nanoplatform





Multifunctional nanoplatform

Synthesis of fluorescent groups





c: 5.10⁻³ M (diclorometano)



Thermometer design

[Ln(btfa)₃(MeOH)(bpeta)] (Ln=Eu & Tb)
β-diketonates

• Organic-inorganic hybrid NPs formed by a maghemite $(\gamma - Fe_2O_3)$ magnetic core coated with a tetraethyl orthosilicate/ aminopropyltriethoxysilane **(TEOS/ APTES)** organosilica shell (modified Stöber method)

• Eu/Tb co-doped NPs with Eu:Tb ratios of 2:1 (NP3-2.1), 1:1 (NP3-1.1), 1:2 (NP3-1.2), 1:3 (NP3-1.3) and 1:10 (NP3-1.10)





EDS mappings

EDS mappings show Eu³⁺ and Tb³⁺ distributions with contours and shapes similar to those of the NPs



The NPs contain both Eu³⁺ and Tb³⁺





Photoluminescence



• 1 & 2: ${}^{5}D_{4} {}^{\ominus}{}^{7}F_{6,5} (Tb^{3+})$ • 3, 4 & 5: ${}^{5}D_{0} {}^{\ominus}{}^{7}F_{2-4} (Eu^{3+})$ • Area marked with an asterisk: $Eu^{3+}/Tb^{3+} ({}^{5}D_{0} {}^{\ominus}{}^{7}F_{0,1})/({}^{5}D_{4} {}^{\ominus}{}^{7}F_{4})$ overlapping Commission Internacionale d'Éclairage (CIE) (x,y) color coordinates illustrates the dependence on T:









Eu/Tb luminescent nanothermometer

- Host rational design; an excited triplet with energy above that of the $Tb^{3+} {}^{5}D_{4}$ state, thus warranting the occurrence of thermally-driven ${}^{5}D_{4}$ \$\circ\$host energy transfer
- ΔE between that triplet state and the Eu^{3+ 5}D₀ emitting level is too large to permit thermally-driven depopulation
- The Tb/Eu relative intensity guarantees absolute measurement of temperature
- The self-calibration (relative intensities) overcomes the well-known drawbacks of intensity-based measurements (*e.g.* sensor concentration and drifts of the lamp and detectors)

Adv. Mater., 2010, 22, 4499; New J. Chem., 2011, 35, 1177 *Spain Patent P200930367*, 2009; PCT/ES2010/070430













Multifunctional nanoplatform





Multifunctional nanoplatform

M3 = FF6@MPEGA+PEGAacac@Eu_{0.25}Tb_{0.75}@DPA Solid Relative Sensitivity and Temperature Range of Operation



- The ∆ parameter presents a temperature dependence almost linear in the temperature range 150-350K.
- The maximum sensitivy is 0.73 %.K⁻¹ at 270 K and the sensitivity is above 0.5 %.K⁻¹ for temperatures T>150Ks





Richard Fleischer, 1966, with Stephen Boyd, Raquel Welch, ...



Based on a novel from Otto Klement and Jerome Bixby, screenplay written by Isaac Asimov





"Biosubmarins" for the s. XXIst







Toxicology issues

Nanopartícles, nanowires, carbon nanotubes, etc. can bring new risks and toxicology problems due to their size.

Attention should be paid to

- fabrication processes
- use
- disposal





Nanopartícles and other nanomaterials can be

- naturals, e.g.: dust
- incidentals, e.g.: polution
- manufactured, e.g.: MNP, CNT



Nanosized materials can be:

- metalic oxides
- nanoclays and nanocomposites
- nanotubes and fullerenes
- quantum dots

Toxicology issues







In nanotoxicology,

- form
- size
- purity

Are about as important as quantity



Designing MNP for Biomedical Applications





Toxicology issues

✓ Blood and urine analysis



No oxidative stress



Mitocondria are not affected





Apoptosis and necrosis at higher concentration



Lysosomes are enlarged or proliferate





Cytotoxicity

Activity of cytosolic **lactate dehydrogenase** in culture medium of OK cells incubated with nanoparticles at different concentrations and times. This activity indicates that cell membrane has broken and intracellular content has leaked.

Top: Four time courses with different concentrations of Fe₂O₃. **14.3 g/L is not toxic, and 28.6 g/L only after 3 days**. **Center**: Dose-responses at different days. Lethal mean concentrations (LC50) are calculated for each curve. **Bottom**: Representation of LC50 evolution with the time, showing that the LC50 diminishes with time, ie. **the effect is accumulative**.

R. Villa-Bellosta *et al.*, Toxicol. Lett., **180**, S221, (2008)







Effect of the nanoparticle diameter on the OK cell death after 7 days of incubation with 0.01 g/l Fe_2O_3

Toxicity is inversely proportional to diameter of the MNPs



Where particles go into the cell?



CAddison Wesley Longman, Inc.

Subcellular localization of fluorescent nanoparticles: LYSOSOMES.



Endoplasmic Reticulum

Mitochondria



The only location of SPIONS in cells are the lysosomes.



Uptake kinetics







(Current work)

Intraperitoneal injection shows No significant effects after 1 month. No damage in organs

Intravenous injection of 5XEndorem shows after 10 days no excess of iron in a variety of tissues neither anomalies in the pathologic anathomy inspection.

Zn-doped modified particles and same doses lead to the same results



Hematotoxicity



Hematotoxicity



Activated partial thromboplastine time (aPTT)

Prothrombine time (PT)



Hematotoxicity



The effect of bioferrofluids on: (A) the prothrombin time (PT) in seconds, (B) the activated partial thromboplastin time (aPTT) in seconds

Lamiaa M.A. Ali, et al., J. Biomed. Nanotechn. (in press) (2013)





Other parameters to control compatibility in blood

Complete blood picture (CBC)

Plasmatic viscosity

- Erythrocyte count
- Leukocyte count
- Hemoglobin
- Platelets





IMAGINATION IS MORE IMPORTANT THAN KNOWLEDGE.

KNOWLEDGE IS LIMITED.

IMAGINATION ENCIRCLES THE WORLD.

A. Einstein



M4 Group

(Multifunctional Magnetic Molecular Materials)





Acknowledgements

A. Millán, R. Piñol, Lamiaa M. A. Ali, R. Bustamante, L. Gabilondo, J. L. Murillo Instituto de Ciencia de Materiales de Aragón CSIC – University of Zaragoza

V. Sorribas Dept. of Molecular Toxicology University of Zaragoza

M. Gutiérrez, R. Cornudella Dept. of Hematology, Faculty of Medicine University of Zaragoza

P.P. Lima, C.D.S. Brites, L.D. Carlos

Dept. of Physics and CICECO Universidade de Aveiro. Portugal